Evotec extends restructuring plan Horizon, shares hover near recent lows
25.06.2026 - 13:49:00 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 13:48.
Evotec SE (DE0005664809) continues to advance its Horizon restructuring program with further site closures and job cuts as part of a multi-year turnaround effort. The Hamburg-based biotech services group is listed in Frankfurt, where its shares recently traded around EUR 4.70, keeping the stock close to 52-week lows in a volatile sector environment as specialist outlets have noted.
What Horizon means for Evotec
Evotec’s overhaul, branded Horizon, aims to streamline operations and restore profitability after revenue weakness and a sharp share price decline over the past two years, according to sector commentary. The program builds on the Priority Reset initiative that started in 2024, shortly after a terminated USD 2.1 billion takeover approach by Halozyme, and targets substantial cost reductions at group level by the end of 2027.
As reported by pharmaphorum, the latest Horizon phase foresees about 800 additional job cuts on top of roughly 600 positions eliminated last year, implying a cumulative reduction of nearly 1,400 roles versus a workforce of about 5,000 at the start of 2026. Management’s goal is to achieve around EUR 75 million in annual cost savings by 2027, helped by concentrating activities on fewer and larger sites with higher utilization and a tighter focus on high-margin discovery and development services.
Site closures and operational footprint
The restructuring also includes closing four more locations, shrinking Evotec’s global footprint materially over the next two years. Pharmaphorum highlights that facilities in Munich in Germany, Abingdon in the UK and Framingham in the US are among the sites slated for shutdown, which will leave the group with roughly ten operational locations worldwide once Horizon is fully implemented.
Evotec’s management has framed the site consolidation as a prerequisite for improving efficiency and capital allocation in its contract research and drug discovery businesses, especially in a weaker outsourcing environment. Industry analyses emphasize that the demand backdrop for contract research organizations has cooled compared with the post-pandemic peak, forcing smaller players to cut fixed costs and refocus on the most profitable segments, where Evotec still sees structural growth opportunities.
Recent numbers show pressure
Financial figures from the first quarter of 2026 underscore the pressure that triggered Horizon and Priority Reset. According to a June 2026 analysis on the biotech and life sciences sector, Evotec generated Q1 2026 revenue of EUR 156.6 million, down about 22 percent year on year, while adjusted EBITDA slipped to a loss of EUR 21.9 million.
The same report notes that the prior-year quarter had been boosted by a one-off license deal, exaggerating the apparent decline, but still confirms that recurring profitability has weakened. Analysts commenting on the numbers stress that the turnaround plan is designed to offset this erosion by cutting structural costs and tightening the project portfolio, although the short-term impact on earnings remains negative because of restructuring expenses.
Chart and technical picture on Frankfurt
On Frankfurt, data from finanzen.net show Evotec shares recently around EUR 4.72, modestly below the previous close and broadly in line with levels cited in sector articles. The stock is far off its historical highs and, according to market commentary, has seen roughly a third of its value erased over the past twelve months, with the latest restructuring headlines pushing it to fresh 52-week lows.
Technical services place the stock in a weak momentum segment within the wider biotechnology and medical research group. For the NASDAQ listing under ticker EVO, TradingKey reports a close at USD 2.69 on 24 June 2026, with the price trading between support at USD 2.47 and resistance around USD 2.99, and a predominantly sell-oriented signal mix based on moving averages and other indicators.
Analyst and sector backdrop
While the Horizon program dominates the short-term narrative, broader life sciences coverage still includes Evotec among structurally relevant discovery service names. In a June 2026 sector piece comparing Evotec with BioNxt Solutions and Merck, commentators describe Evotec’s first quarter as weak but underline that the company’s platform positions it to benefit if biotech funding and outsourcing demand normalize.
The same article notes that the stock trades around EUR 4.66 and that the current valuation leaves scope for upside if management delivers on its turnaround milestones and if the environment for partnering deals improves. Larger sector peers such as Merck act as a reference point for investors assessing contract research and discovery service providers, with Evotec’s risk profile clearly higher but its potential operating leverage also notable once fixed costs are reduced.
Further news and data on the Evotec shares
All current reports, background pieces and price information on Evotec are collected on the dedicated topic page and in the company’s investor relations section.
The business behind the stock
Evotec generates its revenue primarily as a contract research and drug discovery partner for pharmaceutical and biotech companies, operating integrated platforms that span target discovery, hit identification, medicinal chemistry and preclinical development. In addition to fee-for-service work, the group engages in selected co-owned pipeline projects where it receives milestones and potential royalties if partnered assets progress successfully.
Where the stock trades today
The Evotec shares (DE0005664809) trade on the Frankfurt Stock Exchange, where recent data show levels around EUR 4.72 on Stuttgart quotes, with the Xetra price in a similar band on 2026-06-25 at 13:30 CET.
Key data on the Evotec shares
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Frankfurt (Xetra)
- Price (as of 2026-06-25, 13:30): 4.72 EUR
- Market cap: 836.38 million EUR (as of 2026-06-25)
- Sector / industry: Biotechnology & Medical Research
- Index membership: TecDAX
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell any financial instrument. All data were obtained from sources believed to be reliable but cannot be guaranteed. Past performance is not indicative of future results.
